R&D Trends

Cambridge Epigenetix, NuGEN Technologies partner in epigenetics research

Tuesday, August 15, 2017

Cambridge Epigenetix (CEGX) and NuGEN Technologies, leaders in innovative epigenetic technologies, have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits. The signing of the agreement will enable CEGX to focus on its epigenetic biomarker discovery programmes, both in-house and in partnership with leading biopharma companies, and will further strengthen NuGEN’s epigenetics portfolio of whole genome Methyl-Seq, Reduced Representation Bisulfite Sequencing (RRBS), and patented SPET target enrichment systems.

[Read More]

Takeda, Shattuck Labs partner on immuno-oncology

Monday, August 14, 2017

Takeda Pharmaceutical and Shattuck Labs have entered into a research collaboration to explore and develop checkpoint fusion proteins that have the potential to become highly differentiated, next-generation immunotherapies. Under the terms of the collaboration agreement, Takeda will hold options for exclusive global development and commercialization rights for up to four molecules resulting from the collaboration.

[Read More]

Alexion and Sema4 announce strategic partnership

Friday, August 11, 2017

Alexion Pharmaceuticals, Inc. and Sema4 have announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases.

[Read More]

Veritas Genetics acquires Curoverse for AI and Machine Learning in Genomics

Wednesday, August 9, 2017

Veritas Genetics, the genome company, announces the acquisition of Boston-based Curoverse, the preeminent computing and bioinformatics company behind the Personal Genome Project (PGP) at Harvard Medical School, and creator of the open-source platform Arvados. Curoverse software is used by industry leaders such as the Wellcome Trust Sanger Institute to manage, process and share petabytes of genomic and biomedical data as well as facilitate AI and machine learning.

[Read More]

HitGen, LEO Pharma partner

Wednesday, August 9, 2017

HitGen announced that the company has entered into a multi-target multi-year collaboration with LEO Pharma to discover novel small molecule leads for multiple therapeutic targets of interest to LEO Pharma. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from LEO Pharma.

[Read More]

Selvita, Leukemia & Lymphoma Society partner

Tuesday, August 8, 2017

Selvita S.A. and The Leukemia & Lymphoma Society have announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML). Selvita has discovered and is developing SEL120, a therapy that targets the cyclin-dependent kinase 8 (CDK8) protein, which plays a unique and critical role in gene regulation. Laboratory studies have shown the agent to be effective in certain types of AML cells. [Read More]

Agilis Biotherapeutics, Gene Therapy Research Institution partner

Friday, August 4, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution (GTRI), a corporation with the mission of developing and delivering of the safest and most efficient gene therapies, announced that the companies have completed a manufacturing and collaboration partnership joint venture (JV) to advance adeno-associated virus (AAV) gene therapies. The JV was initiated earlier this year in connection with a grant from the Japanese Ministry of Trade, Economics and Industry (METI) and Japan External Trade Organization (JETRO) for the development of a state-of-the-art AAV manufacturing facility in Japan. GTRI was co-founded by Professor Shin-ichi Muramatsu, M.D., a leading pioneer in gene therapy who has performed basic science and clinical research in the field for over two decades.

[Read More]